Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP + pneumococcal conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
DTaP-Pfizer-pneumococcal infection refers to the co-administration of Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13, brand name Prevnar 13) or 7-valent pneumococcal conjugate vaccine (7vPnC) with a diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. This regimen has been evaluated for safety, tolerability, and immunogenicity in healthy infants, particularly in the Japanese population. The pneumococcal component consists of capsular polysaccharides from multiple Streptococcus pneumoniae serotypes conjugated to the CRM197 carrier protein, while the DTaP component contains toxoids and purified antigens from Corynebacterium diphtheriae, Clostridium tetani, and Bordetella pertussis. The combination aims to provide comprehensive protection against invasive pneumococcal disease, pneumonia, diphtheria, tetanus, and pertussis through a synchronized dosing schedule.
- Brand names
- Prevnar 13Prevnar13Prevnar-13Prevenar
- Other names
- DTaP-Pfizer-pneumococcal infection7vPnC13vPnCPCV13PCV-13PCV 13PCV7PCV-7PCV 7DTaP + PCV13DTaP + PCV7
02
Targets
PRN (Pertactin)Diphtheria toxinCPS (Streptococcus pneumoniae capsular polysaccharide)FIM2/FIM3 (Fimbriae types 2 and 3)FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on DTaP + pneumococcal conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP + pneumococcal conjugate vaccine.